The overall goal of this competing renewal SPORE in skin Cancer from The University of Texas M.D. Anderson Cancer Center is to facilitate innovative translational research in the prevention, detection and treatment of melanoma leading to the elimination of the disease. This SPORE aims to achieve this goal by assembling a talented group of scientists who are committed to the translation of melanoma-specific findings from the laboratory to the clinic as well as from the clinic to the laboratory. The University of Texas M.D. Anderson Cancer Center has prioritized the elimination of melanoma as a health risk, and to this end established in 1998, a Multidisciplinary Research Program in Melanoma to support training and research across traditional administrative boundaries. The program provided resources and a structure that led to our successful funding in 2004 for the first SPORE dedicated entirely to Melanoma, which allowed us to further advance along several translational themes and provide a basis for this renewal application. This SPORE in Melanoma proposes five translational projects, four of which included treatment protocols to begin in successive years and takes advantage of our large melanoma patient population. The five projects and four protocols are served by three cores: Administrative (A), Informatics, Tissue Resource, and Pathology (B), and Biostatics and Bioinformatics (C). The Developmental Research Program (DRP) and Career Development Program (CDP) continue as successful aspects of our SPORE as each new project incorporates at least one DRP/CDP awardee as a new Co-Leader. The five proposed projects address activation of Toll-Like Receptors (TLR) for specific immune stimulation (#1);inhibition of pSTAT3 for control of melanoma metastasis focused in the CNS (#2);elucidation of melanoma JNOS-related inflammation for development of a prognostic signature as well as a target therapy (#3);systemic deliver of angiogenesis inhibitors using nanoliposomal technology (#4);and genetic mechanisms of immunity and inflammation to generate an integrated risk model as part of a population based project (#5). Through this research program and with the full support of The University of Texas M.D. Anderson Cancer Center, this SPORE aims to make a significant impact toward the prevention, detection, and treatment of melanoma in patients.
Melanoma is the most deadly form of skin cancers, and the incidence is increasing faster than any other cancer in the US at this time. The metastatic process is poorly understood, and new therapies are needed urgently. This SPORE directly addresses solving these issues through innovative translational research.
|Ling, Hui; Pickard, Karen; Ivan, Cristina et al. (2016) The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis. Gut 65:977-89|
|Kim, Sun-Hee; Hashimoto, Yuuri; Cho, Sung-Nam et al. (2016) Microsomal PGE2 synthase-1 regulates melanoma cell survival and associates with melanoma disease progression. Pigment Cell Melanoma Res 29:297-308|
|Oba, Junna; Wei, Wei; Gershenwald, Jeffrey E et al. (2016) Elevated Serum Leptin Levels are Associated With an Increased Risk of Sentinel Lymph Node Metastasis in Cutaneous Melanoma. Medicine (Baltimore) 95:e3073|
|Van Roosbroeck, Katrien; Fanini, Francesca; Setoyama, Tetsuro et al. (2016) Combining anti-miR-155 with chemotherapy for the treatment of lung cancers. Clin Cancer Res :|
|Roszik, Jason; Haydu, Lauren E; Hess, Kenneth R et al. (2016) Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Med 14:168|
|Paladini, Laura; Fabris, Linda; Bottai, Giulia et al. (2016) Targeting microRNAs as key modulators of tumor immune response. J Exp Clin Cancer Res 35:103|
|Siiskonen, Satu J; Zhang, Mingfeng; Li, Wen-Qing et al. (2016) A Genome-Wide Association Study of Cutaneous Squamous Cell Carcinoma among European Descendants. Cancer Epidemiol Biomarkers Prev 25:714-20|
|Roszik, Jason; Wu, Chang-Jiun; Siroy, Alan E et al. (2016) Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression. Sci Rep 6:19649|
|Han, Jun; Walters, James T R; Kirov, George et al. (2016) Gender differences in CNV burden do not confound schizophrenia CNV associations. Sci Rep 6:25986|
|Vaysse, Amaury; Fang, Shenying; Brossard, Myriam et al. (2016) A comprehensive genome-wide analysis of melanoma Breslow thickness identifies interaction between CDC42 and SCIN genetic variants. Int J Cancer 139:2012-20|
Showing the most recent 10 out of 250 publications